Marek Broul , Jan Milota , Miroslav Šuráň , Vít Horák , Aneta Hujová , Michaela Liegertová
{"title":"Late cutaneous metastasis of clear-cell renal cell carcinoma to the lower eyelid five years after radical nephrectomy: A case report","authors":"Marek Broul , Jan Milota , Miroslav Šuráň , Vít Horák , Aneta Hujová , Michaela Liegertová","doi":"10.1016/j.eucr.2025.103225","DOIUrl":null,"url":null,"abstract":"<div><div>Clear-cell renal cell carcinoma (ccRCC) metastasises widely, but cutaneous spread is uncommon and eyelid involvement exceptionally rare. We report a 55-year-old man who developed a painless 4-mm lower-eyelid nodule five years after curative left radical nephrectomy for pT1a ccRCC. Excision confirmed metastatic ccRCC (PAX8+, CD10<sup>+</sup>). Staging showed mediastinal nodal and pulmonary disease. First-line avelumab 800 mg IV every two weeks plus axitinib was initiated; in July 2025 axitinib was reduced to 5 mg once daily. After eight cycles, interim CT (August 2025) demonstrated regression with no locoregional recurrence. This case highlights continued vigilance and prompt biopsy of atypical eyelid lesions.</div></div>","PeriodicalId":38188,"journal":{"name":"Urology Case Reports","volume":"63 ","pages":"Article 103225"},"PeriodicalIF":0.4000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214442025002967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Clear-cell renal cell carcinoma (ccRCC) metastasises widely, but cutaneous spread is uncommon and eyelid involvement exceptionally rare. We report a 55-year-old man who developed a painless 4-mm lower-eyelid nodule five years after curative left radical nephrectomy for pT1a ccRCC. Excision confirmed metastatic ccRCC (PAX8+, CD10+). Staging showed mediastinal nodal and pulmonary disease. First-line avelumab 800 mg IV every two weeks plus axitinib was initiated; in July 2025 axitinib was reduced to 5 mg once daily. After eight cycles, interim CT (August 2025) demonstrated regression with no locoregional recurrence. This case highlights continued vigilance and prompt biopsy of atypical eyelid lesions.